Last reviewed · How we verify
Sinemet 25-100 Oral Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Sinemet 25-100 Oral Tablet (Sinemet 25-100 Oral Tablet) — XenoPort, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sinemet 25-100 Oral Tablet TARGET | Sinemet 25-100 Oral Tablet | XenoPort, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sinemet 25-100 Oral Tablet CI watch — RSS
- Sinemet 25-100 Oral Tablet CI watch — Atom
- Sinemet 25-100 Oral Tablet CI watch — JSON
- Sinemet 25-100 Oral Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Sinemet 25-100 Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/sinemet-25-100-oral-tablet. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab